BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 11863094)

  • 1. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial.
    Fizazi K; Do KA; Wang X; Finn L; Logothetis CJ; Amato RJ
    Ann Oncol; 2002 Jan; 13(1):125-34. PubMed ID: 11863094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
    J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors.
    Culine S; Théodore C; Bekradda M; Farhat F; Terrier-Lacombe MJ; Droz JP
    Am J Clin Oncol; 1997 Apr; 20(2):184-8. PubMed ID: 9124197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
    Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
    Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum for advanced germ cell testis tumors: Brazilian experience.
    Srougi M; Simon SD; de Góes GM
    J Urol; 1985 Jul; 134(1):65-9. PubMed ID: 2409300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).
    Culine S; Kerbrat P; Kramar A; Théodore C; Chevreau C; Geoffrois L; Bui NB; Pény J; Caty A; Delva R; Biron P; Fizazi K; Bouzy J; Droz JP;
    Ann Oncol; 2007 May; 18(5):917-24. PubMed ID: 17351252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential trials of cisplatin, vinblastine, and bleomycin and etoposide and cisplatin in disseminated nonseminomatous germ cell tumors of the testis with a good prognosis at a single institution.
    Germá JR; Sagarra AF; Izquierdo MA; Seguí MA
    Cancer; 1993 Feb; 71(3):796-803. PubMed ID: 7679314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors.
    Ozols RF; Ihde DC; Linehan WM; Jacob J; Ostchega Y; Young RC
    J Clin Oncol; 1988 Jun; 6(6):1031-40. PubMed ID: 2453619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.
    Bosl GJ; Geller NL; Bajorin D; Leitner SP; Yagoda A; Golbey RB; Scher H; Vogelzang NJ; Auman J; Carey R
    J Clin Oncol; 1988 Aug; 6(8):1231-8. PubMed ID: 2457657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis.
    Logothetis CJ; Samuels ML; Selig D; Swanson D; Johnson DE; von Eschenbach AC
    J Clin Oncol; 1985 Mar; 3(3):326-35. PubMed ID: 2579213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients.
    Logothetis CJ; Samuels ML; Selig DE; Ogden S; Dexeus F; Swanson D; Johnson D; von Eschenbach A
    Am J Med; 1986 Aug; 81(2):219-28. PubMed ID: 2426944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.
    Christian JA; Huddart RA; Norman A; Mason M; Fossa S; Aass N; Nicholl EJ; Dearnaley DP; Horwich A
    J Clin Oncol; 2003 Mar; 21(5):871-7. PubMed ID: 12610187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive chemotherapy for metastatic nonseminomatous germ cell tumors.
    Logothetis CJ; Chong C; Dexeus FH; Sella A; Ogden S
    Prog Clin Biol Res; 1990; 350():301-7. PubMed ID: 1696741
    [No Abstract]   [Full Text] [Related]  

  • 15. [Chemotherapeutic effectiveness in malignant testicular tumors at advanced stages. Preliminary results of the VAB VI program].
    Chiricuţă I; Ghilezan N
    Rev Chir Oncol Radiol O R L Oftalmol Stomatol Chir; 1985; 34(6):455-68. PubMed ID: 2421373
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleomycin in germ cell testicular tumors (GCTT).
    Germa Lluch JR
    Prog Clin Biol Res; 1985; 203():381-9. PubMed ID: 2421332
    [No Abstract]   [Full Text] [Related]  

  • 18. [Total remission of advanced cancer of the testis with the use of the VAB6 schedule: experience with 40 cases].
    Srougi M; Simon SD; de Góes GM
    AMB Rev Assoc Med Bras; 1985; 31(3-4):52-8. PubMed ID: 2417287
    [No Abstract]   [Full Text] [Related]  

  • 19. [Preliminary evaluation of the toxicity and effectiveness of chemotherapy using the VAB-6 protocol in the treatment of non-seminoma of the testis].
    Madej G; Gigier A; Siedlecki P; Pieńkowski T
    Nowotwory; 1987; 37(1):44-9. PubMed ID: 2442730
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
    Kawai K; Hinotsu S; Oikawa T; Sekido N; Hattori K; Miyanaga N; Hasegawa Y; Kojima H; Shimazui T; Akaza H
    Jpn J Clin Oncol; 2006 Nov; 36(11):723-30. PubMed ID: 17082218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.